Endoscopic retrograde cholangiopancreatography for bile duct stones in patients with a performance status score of 3 or 4.
Complication
Endoscopic retrograde Cholangiopancreatography
Performance status
Risk factor
Journal
World journal of gastrointestinal endoscopy
ISSN: 1948-5190
Titre abrégé: World J Gastrointest Endosc
Pays: United States
ID NLM: 101532474
Informations de publication
Date de publication:
16 Apr 2022
16 Apr 2022
Historique:
received:
17
11
2021
revised:
22
01
2022
accepted:
16
03
2022
entrez:
31
5
2022
pubmed:
1
6
2022
medline:
1
6
2022
Statut:
ppublish
Résumé
As the aging population grows worldwide, the rates of endoscopic retrograde cholangiopancreatography (ERCP) for common bile duct stones (CBDS) in older patients with a poor performance status (PS) have been increasing. However, the data on the safety and efficacy of ERCP for CBDS in patients with a PS score of 3 or 4 are lacking, with only a few studies having investigated this issue among patients with poor PS. To examine the safety and efficacy of ERCP for CBDS in patients with a PS score of 3 or 4. This study utilized a retrospective multi-centered design of three institutions in Japan for 8 years to identify a total of 1343 patients with CBDS having native papillae who underwent therapeutic ERCP. As a result, 1113 patients with a PS 0-2 and 230 patients with a PS 3-4 were included. One-to-one propensity-score matching was performed to compare the safety and efficacy of ERCP for CBDS between patients with a PS 0-2 and those with a PS 3-4. The overall ERCP-related complication rates in all patients and propensity score-matched patients with a PS 0-2 and 3-4 were 9.0% (100/1113) and 7.0% (16/230; ERCP for CBDS can be effectively performed in patients with a PS 3 or 4. Nevertheless, the indication for ERCP in such patients should be carefully considered with prophylactic antibiotics.
Sections du résumé
BACKGROUND
BACKGROUND
As the aging population grows worldwide, the rates of endoscopic retrograde cholangiopancreatography (ERCP) for common bile duct stones (CBDS) in older patients with a poor performance status (PS) have been increasing. However, the data on the safety and efficacy of ERCP for CBDS in patients with a PS score of 3 or 4 are lacking, with only a few studies having investigated this issue among patients with poor PS.
AIM
OBJECTIVE
To examine the safety and efficacy of ERCP for CBDS in patients with a PS score of 3 or 4.
METHODS
METHODS
This study utilized a retrospective multi-centered design of three institutions in Japan for 8 years to identify a total of 1343 patients with CBDS having native papillae who underwent therapeutic ERCP. As a result, 1113 patients with a PS 0-2 and 230 patients with a PS 3-4 were included. One-to-one propensity-score matching was performed to compare the safety and efficacy of ERCP for CBDS between patients with a PS 0-2 and those with a PS 3-4.
RESULTS
RESULTS
The overall ERCP-related complication rates in all patients and propensity score-matched patients with a PS 0-2 and 3-4 were 9.0% (100/1113) and 7.0% (16/230;
CONCLUSION
CONCLUSIONS
ERCP for CBDS can be effectively performed in patients with a PS 3 or 4. Nevertheless, the indication for ERCP in such patients should be carefully considered with prophylactic antibiotics.
Identifiants
pubmed: 35634487
doi: 10.4253/wjge.v14.i4.215
pmc: PMC9048491
doi:
Types de publication
Journal Article
Langues
eng
Pagination
215-225Informations de copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors declare that there are no conflicts of interest in relation to this article.
Références
Lancet. 1996 Sep 21;348(9030):791-3
pubmed: 8813987
Dig Dis Sci. 2016 Jul;61(7):2094-101
pubmed: 26873537
World J Gastroenterol. 2016 Oct 7;22(37):8382-8388
pubmed: 27729744
J Rural Med. 2019 Nov;14(2):226-230
pubmed: 31788147
J Gastroenterol Hepatol. 2014 Nov;29(11):1943-8
pubmed: 24730577
Endosc Int Open. 2016 Jan;4(1):E83-90
pubmed: 26793790
PLoS One. 2018 Jan 3;13(1):e0190665
pubmed: 29298346
Endoscopy. 2020 Feb;52(2):127-149
pubmed: 31863440
Dig Dis Sci. 2021 Apr;66(4):1291-1296
pubmed: 32440744
Gastrointest Endosc. 2006 Mar;63(3):417-23
pubmed: 16500389
Gastrointest Endosc. 2006 Dec;64(6):899-905
pubmed: 17140895
Intern Med. 2010;49(18):1935-41
pubmed: 20847495
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Intern Med. 2019 Aug 1;58(15):2125-2132
pubmed: 30996182
Gut Liver. 2014 Sep;8(5):552-6
pubmed: 25228977
Gastrointest Endosc. 2010 Mar;71(3):446-54
pubmed: 20189503
J Dig Dis. 2018 Oct;19(10):626-634
pubmed: 30117280
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313